Kadmon Holdings Inc., of New York, said the first patient was dosed in a 150-participant, double-blind, placebo-controlled phase II trial of KD025, the company's oral inhibitor of Rho-associated coiled-coil kinase 2, in moderate to severe chronic plaque psoriasis.